These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17951100)

  • 21. The theoretical basis of cancer-stem-cell-based therapeutics of cancer: can it be put into practice?
    Sánchez-García I; Vicente-Dueñas C; Cobaleda C
    Bioessays; 2007 Dec; 29(12):1269-80. PubMed ID: 18022789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapies to improve tumor immunotherapy.
    Begley J; Ribas A
    Clin Cancer Res; 2008 Jul; 14(14):4385-91. PubMed ID: 18628452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective anticancer strategies via intervention of the death pathways relevant to cell transformation.
    Li QX; Yu DH; Liu G; Ke N; McKelvy J; Wong-Staal F
    Cell Death Differ; 2008 Aug; 15(8):1197-210. PubMed ID: 18437165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell death in hematological tumors.
    Fulda S
    Apoptosis; 2009 Apr; 14(4):409-23. PubMed ID: 19130230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative.
    Peggs KS; Segal NH; Allison JP
    Cancer Cell; 2007 Sep; 12(3):192-9. PubMed ID: 17785201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis.
    Dorer DE; Nettelbeck DM
    Adv Drug Deliv Rev; 2009 Jul; 61(7-8):554-71. PubMed ID: 19394376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.
    Thorne SH; Contag CH
    Gene Ther; 2008 May; 15(10):753-8. PubMed ID: 18356814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Search for "weapons of mass destruction" for cancer -- immuno/ gene therapy comes of age.
    Wei MQ; Metharom P; Ellem KA; Barth S
    Cell Mol Immunol; 2005 Oct; 2(5):351-7. PubMed ID: 16368061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
    Wallerand H; Reiter RR; Ravaud A
    Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunotherapy for cancer--modern immunologic strategies in oncology].
    Halama N; Zoernig I; Jäger D
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting apoptosis as an approach for gastrointestinal cancer therapy.
    Qiao L; Wong BC
    Drug Resist Updat; 2009 Jun; 12(3):55-64. PubMed ID: 19278896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression profiling of non-small-cell lung cancer.
    Lacroix L; Commo F; Soria JC
    Expert Rev Mol Diagn; 2008 Mar; 8(2):167-78. PubMed ID: 18366303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of emodin on the gene expression profiling of human breast carcinoma cells.
    Huang Z; Chen G; Shi P
    Cancer Detect Prev; 2009; 32(4):286-91. PubMed ID: 19185431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Designer therapies for glioblastoma multiforme.
    Sathornsumetee S; Rich JN
    Ann N Y Acad Sci; 2008 Oct; 1142():108-32. PubMed ID: 18990124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to chemotherapy and hormone therapy in endometrial cancer.
    Chaudhry P; Asselin E
    Endocr Relat Cancer; 2009 Jun; 16(2):363-80. PubMed ID: 19190080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heat shock proteins: stress proteins with Janus-like properties in cancer.
    Calderwood SK; Ciocca DR
    Int J Hyperthermia; 2008 Feb; 24(1):31-9. PubMed ID: 18214767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IAP-targeted therapies for cancer.
    LaCasse EC; Mahoney DJ; Cheung HH; Plenchette S; Baird S; Korneluk RG
    Oncogene; 2008 Oct; 27(48):6252-75. PubMed ID: 18931692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
    Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
    Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.